EXECUTIVE LEADERSHIP TEAM
ANA ANDREAZZA
Executive Director
Dr. Andreazza, a Professor in the Departments of Pharmacology & Toxicology and Psychiatry, holds the esteemed Tier II Canada Research Chair in Molecular Pharmacology of Mood Disorders and the Thomas C. Zachos Chair in Mitochondrial Research. Dr. Andreazza is also the visionary founder of MITO2i,
SONYA BRIJBASSI
Associate Director, Strategy and Partnerships
Sonya joined the University of Toronto’s Innovations & Partnerships Office in 2007, initially as a Commercialization Manager for the Life Sciences team, focusing on moving research projects into practical applications. In 2013, she transitioned to the role of Business Development Officer, Industry Partnerships, facilitating sponsored research, industry interactions, and strategic collaborations.
DAVID BODENSTEIN
Director, Technology and Innovations
Dr. Bodenstein is a Banting Postdoctoral Fellow developing novel therapeutic strategies for mitochondrial dysfunction in cardiac and brain diseases using patient-derived 2D and 3D cellular models. As the Director of Technology and Innovation at MITO2i, he oversees development of new research programs that promote technological advancement and translational impact that align with patient needs.
KATE MURRAY
Patient Engagement Lead
Kate Murray leads MitoCanada with heart, vision, and an unwavering commitment to the community. A longtime advocate and changemaker, Kate believes that by uniting lived experiences and voices, we can break down barriers, improve health outcomes, and co-create solutions that spark lasting change.
MADELINE DOUGHERTY
Knowledge Transfer and Communications Officer
Madeline has joined the team as the Knowledge Transfer and Communications Officer. Her responsibilities include creating social media content, updating website content, and communicating scientific knowledge to the public and patients.
EILEEN HAYDARIAN
Social Coordinator
